Literature DB >> 12766605

Non-invasive adrenal imaging in primary aldosteronism. Sensitivity and positive predictive value of radiocholesterol scintigraphy, CT scan and MRI.

F Lumachi1, M C Marzola, P Zucchetta, A Tregnaghi, D Cecchin, G Favia, F Bui.   

Abstract

The aim of this study was to evaluate the sensitivity and positive predictive value (PPV) of dexamethasone-suppression norcholesterol scintigraphy (NCS), computed tomography (CT) scanning and magnetic resonance imaging (MRI) in patients with primary aldosteronism (PA) who had undergone unilateral adrenalectomy. A series of 49 patients with confirmed PA was reviewed. There were 18 (36.7%) men and 31 (63.3%) women, with a median age of 47 years (range, 23-66 years). NCS was performed in all patients, and 46 (93.9%) and 31 (63.2%) underwent CT scan and MRI, respectively. Final pathology showed an aldosterone-producing adenoma in 45 (91.8%) patients, unilateral nodular cortical hyperplasia (NCH) in two (4.1%) and unilateral microscopic cortical hyperplasia (MCH) in two (4.1%). No aldosterone-producing carcinoma or bilateral adenomas were found. The greatest diameter of the removed adrenal tumour was in the range 8-40 mm (median, 14 mm). The PPV of adrenal imaging was 97.6% for NCS, 85.0% for CT scan (P=0.04) and 83.3% for MRI (P=0.03), and the sensitivity was 85.4%, 85.0% and 74.1%, respectively (P=NS). The age and the main biochemical parameters did not differ significantly (P=NS) between patients with true positive and false negative results of the imaging procedures. NCS accurately depicted all patients with NCH and MCH, whilst CT scan and MRI failed to diagnose such unilateral adrenal gland hyperfunction in two and three patients, respectively. The overall sensitivity of combined NCS and CT scan was 100%. In conclusion, in patients with PA, both NCS and CT scan are necessary to confirm the exclusive unilateral adrenal hyperfunction and, subsequently, to establish the appropriate treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766605     DOI: 10.1097/00006231-200306000-00011

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

Review 1.  Noninvasive adrenal imaging in hyperaldosteronism.

Authors:  Daniel R Simon; Michael A Palese
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

2.  Noninvasive adrenal imaging in hyperaldosteronism: is it accurate for correctly identifying patients who should be selected for surgery?

Authors:  Celestino Pio Lombardi; Marco Raffaelli; Carmela De Crea; Vittoria Rufini; Giorgio Treglia; Rocco Bellantone
Journal:  Langenbecks Arch Surg       Date:  2007-01-23       Impact factor: 3.445

3.  NP-59 test for preoperative localization of primary hyperaldosteronism.

Authors:  Marcello Di Martino; Iñigo García Sanz; Jose Luis Muñoz de Nova; Cristina Marín Campos; Miguel Martínez Martín; Luis Domínguez Gadea
Journal:  Langenbecks Arch Surg       Date:  2017-02-21       Impact factor: 3.445

Review 4.  Approach to the surgical management of primary aldosteronism.

Authors:  Maurizio Iacobone; Marilisa Citton; Giovanni Viel; Gian Paolo Rossi; Donato Nitti
Journal:  Gland Surg       Date:  2015-02

5.  Diagnostic performance of CT versus MR in detecting aldosterone-producing adenoma in primary hyperaldosteronism (Conn's syndrome).

Authors:  R K Lingam; S A Sohaib; A G Rockall; A M Isidori; S Chew; J P Monson; A Grossman; G M Besser; R H Reznek
Journal:  Eur Radiol       Date:  2004-07-06       Impact factor: 5.315

Review 6.  Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.

Authors:  Laurence Amar; Pierre-François Plouin; Olivier Steichen
Journal:  Orphanet J Rare Dis       Date:  2010-05-19       Impact factor: 4.123

7.  NP-59 SPECT/CT imaging in stage 1 hypertensive and atypical primary aldosteronism: a 5-year retrospective analysis of clinicolaboratory and imaging features.

Authors:  Yi-Chun Chen; Jainn-Shiun Chiu; Yuh-Feng Wang
Journal:  ScientificWorldJournal       Date:  2013-10-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.